global disparities in access to randomized controlled trials for pulmonary arterial hypertension

Original title: “Global disparities in access to randomized controlled trials for pulmonary arterial hypertension.”

early detection treatment initiation and long term health outcomes in patients with connective tissue disease associated pulmonary arterial hypertension a systematic literature review and expert consensus

Original title: “Early detection, treatment initiation, and long-term health outcomes in patients with connective tissue disease-associated pulmonary arterial hypertension: A systematic literature review and expert consensus.”

selexipag in systemic sclerosis associated pulmonary arterial hypertension long term real world data from a multicentre italian cohort

Original title: “Selexipag in systemic sclerosis-associated pulmonary arterial hypertension: long-term real-world data from a multicentre Italian cohort.”

european respiratory society clinical practice guidelines update for the treatment of pulmonary arterial hypertension

Original title: “European Respiratory Society clinical practice guidelines update for the treatment of pulmonary arterial hypertension.”

delays in the diagnosis and management of pulmonary arterial hypertension a simulated patient cases study across four european countries

Original title: “Delays in the diagnosis and management of pulmonary arterial hypertension: a simulated patient cases study across four European countries.”

Clinical worsening was a composite of death, hospitalization for worsening disease, and other progression measures. The components are not equivalent. Were there downsides? Yes. The Lancet reported more treatment discontinuations related to adverse events on ralinepag than on placebo. Who funded the trial? United Therapeutics, which developed the drug. The trial was randomized, double-blind, and placebo-controlled. What is PAH? A rare ... Clinical worsening was a composite of death, hospitalization for worsening disease, and other progression measures. The components are not equivalent. Were there downsides? Yes. The Lancet reported more treatment discontinuations related to adverse events on ralinepag than on placebo. Who funded the trial? United Therapeutics, which developed the drug. The trial was randomized, double-blind, and placebo-controlled. What is PAH? A rare progressive disease in which lung arteries narrow and stiffen, raising pressure and straining the right side of the heart. Published Lancet results show ralinepag reduced clinical worsening in PAH by 55%. The drug is still investigational and not FDA-approved. Treatment has improved substantially over three decades, and the paper is clear that long-term survival remains poor. The trial population reflects modern practice rather than untreated disease. Eighty percent of participants were already on two background therapies, and 70% were in the milder of the two functional classes that dominate PAH trials. That does not invalidate a randomized, double blind, placebo-controlled trial published in a major journal, and the design is the strongest available. It does mean the framing in company materials, which describes the results as exceptional and as potentially redefining PAH treatment, is promotional language rather than a scientific characterization. Context helps explain why an 18-point difference matters here. Pulmonary arterial hypertension is a rare disease in which the arteries carrying blood from the heart to the lungs narrow and stiffen.

Original title: “Lancet Results Show Ralinepag Cut Clinical Worsening by 55 Percent in Pulmonary Arterial Hypertension”

clinical practice of pulmonary arterial hypertension pah and potential barriers to intensive treatment among pah specialized and non pah specialized centers in japan

Original title: “Clinical Practice of Pulmonary Arterial Hypertension (PAH) and Potential Barriers to Intensive Treatment Among PAH-Specialized and Non-PAH-Specialized Centers in Japan.”

haemodynamic partial remission as a prognostic target in pulmonary arterial hypertension

Original title: “Haemodynamic partial remission as a prognostic target in pulmonary arterial hypertension.”

misdiagnosed as idiopathic pah methylmalonic acidemia as a reversible cause of pediatric pulmonary hypertension

Original title: “Misdiagnosed as Idiopathic PAH: Methylmalonic Acidemia as a Reversible Cause of Pediatric Pulmonary Hypertension.”

long term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension the fonce htap randomized controlled trial

Original title: “Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the FONCE-HTAP randomized controlled trial.”

Insmed’s inhalable candidate showed “impressive” long-term efficacy in pulmonary arterial hypertension, according to analysts at Guggenheim Partners, with functional and biomarker improvements through one year of follow-up.

Original title: “Insmed moves closer to $6B opportunity as PAH drug shows long-term durability”

challenging combination of a high cardiac output and pulmonary arterial hypertension

Original title: “The challenging combination of a high cardiac output and pulmonary arterial hypertension.”

extended follow up of cd19 car t cell therapy in connective tissue disease associated pulmonary arterial hypertension

Original title: “Extended follow-up of CD19 CAR T-cell therapy in connective tissue disease-associated pulmonary arterial hypertension.”

three dimensional micro ct analysis of vascular remodeling and vascular pruning in pulmonary arterial hypertension

Original title: “Three-dimensional micro-CT analysis of vascular remodeling and vascular pruning in pulmonary arterial hypertension.”

sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension

Original title: “Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension.”

variation in snx29 and acute vasodilator response in pulmonary arterial hypertension

Original title: “Variation in SNX29 and Acute Vasodilator Response in Pulmonary Arterial Hypertension.”

acute hemodynamic effects of tpn171h in pulmonary arterial hypertension a randomized controlled phase 2a trial

Original title: “Acute hemodynamic effects of TPN171H in pulmonary arterial hypertension: a randomized, controlled, phase 2a trial.”

prognostic performance of esc ers guideline recommended echocardiographic risk markers in prevalent pulmonary arterial hypertension

Original title: “Prognostic performance of ESC/ERS guideline-recommended echocardiographic risk markers in prevalent pulmonary arterial hypertension.”

application of a prevalence adjusted cost effectiveness threshold framework for pulmonary arterial hypertension

Original title: “Application of a Prevalence-Adjusted Cost-Effectiveness Threshold Framework for Pulmonary Arterial Hypertension.”